Cell and Gene Outsourcing

  1. Quality GMP-Grade iPSC And Knockin-Ready TARGATT™ iPSC 1/23/2025

    To jump start iPSC derived therapeutic cell product development; achieve reliable and efficient genome integration with our innovative solutions.

  2. Improving ISR Success Rates In Bioanalysis Of Small Molecule Drugs 1/23/2025

    Leveraging incurred sample reanalysis (ISR) in your quality control can help your team mitigate risks, establish regulatory compliance, maintain data integrity, and instill confidence in your pharmacokinetic modeling.

  3. Gene Editing Services 1/21/2025

    Choose from our different technology platforms or ask our scientists to customize a project to achieve your goals. We’ll use our patented and proprietary technologies, such as our Rapid Automated Cell Line Editing (RACE™) protocol, to ensure quality, accuracy, and fast turnaround times.

  4. The Leader In Fill/Finish 1/17/2025

    Discover how our advanced fill-finish manufacturing capabilities can elevate the success of your project, streamlining processes and enhancing quality at every step.

  5. Beyond CRISPR: Exploring Next-Generation Gene Editing With TARGATT, Mad7, And Base Editing 1/17/2025

    Consider several groundbreaking gene editing technologies—TARGATT®, Mad7, and Base Editing—and gain insights into their transformative applications in genetic engineering and therapeutic development.

  6. The Future Of Allogeneic Cell Therapy: Hypoimmunogenic Donor Cells 1/17/2025

    Explore how TARGATT® gene editing and HLA-F technologies are revolutionizing hypoimmunogenic cell development for scalable allogeneic therapies.

  7. CGMP-Validated RCL Assay Used For Release Testing Of Manufactured Viruses, Gene Mediated Cell Therapy Products 1/17/2025

    Ensure the safety and efficacy of lentiviral-based therapies by addressing the risks of replication-competent lentiviruses (RCLs) through advanced monitoring and control strategies.

  8. Successful Regulatory Submission Via The Trifecta Of Awesomeness 1/17/2025

    Three essential elements contribute to a repeatable, adaptable regulatory submission process: strategic planning, team engagement, and properly leveraging team experience.

  9. Building Frameworks To Support Complex Therapy Manufacturing 1/16/2025

    To make its clinical product, CLBR001+SWI019, the Calibr-Skaggs Institute for Innovative Medicines relies on a complex network of contractors from around the globe.

  10. Know Your Product, Know Your Path: A Primer On Advanced Therapy Development 1/16/2025

    To prevent path-to-market setbacks, it is critical to develop a CMC strategy that proactively identifies scientific and compliance gaps, as well as mitigates risk.